PepTalk 2017
PepTalk 2017
Pipeline One Header

Cambridge Healthtech Institute’s Fourth Annual
Enhancing Antibody Binding and Specificity
Scientific Strategies for Engineering Biotherapeutic Binding and Specificity
for Next-Generation Antibody Therapeutics

January 10-11, 2017 | Hilton San Diego Bayfront | San Diego, CA


As the industry expands its repertoire of antibody drug products into new therapeutic areas, product formats and protein constructs, the control of antibody/antigen targeting, binding and specificity will take on a new level of importance for researchers in this field. The second meeting in the PepTalk Protein Engineering & Development pipeline, Enhancing Antibody Binding and Specificity, presents innovative approaches to the modulation of binding activity, mechanism of action and difficult target challenges such as transmembrane proteins and intracellular targeting.

Preliminary Agenda


KEYNOTE PRESENTATION: Antibody Generation and Selection: A Very Different Fetal Life

Eric R.F. Meffre, Ph.D., Associate Professor, Immunobiology, Yale University School of Medicine



ANALYTICAL METHODS

Toward an Integrated Biosensor Platform to Support Biotherapeutic Discovery

Kerry Kelleher, Ph.D., Principal Research Scientist, BioMedicine Design, Pfizer

KinExA vs. SPR and ELISa Binding Characterization

Alexander Ivanov, Ph.D., Senior Scientist, Global Biologics, Abbvie Bioresearch Center

Epitope Binning and Characterization at the Early Stages of Therapeutic Antibody Discovery

Sam Wu, Ph.D., Principal Scientist, Biologics Research, Janssen BioTherapeutics


REGULATING TARGET SELECTIVITY IN BISPECIFIC ANTIBODIES

Optimizing T Cell Engaging Full Length Bispecific Antibodies

Javier Chaparro-Riggers, Ph.D., Director, Antibody Technology, Pfizer

Enhancing Tumor-Targeting Selectivity by Modulating Bispecific Antibody’s Binding Affinity and Format Valence

Yariv Mazor, Ph.D., Scientist, Antibody Discovery & Protein Engineering, MedImmune


INTRACELLULAR TARGETS

Targeting Undruggable Proteins with Antibodies

David A. Scheinberg, M.D., Ph.D., Vincent Astor Chair and Chairman, Molecular Pharmacology Program, Sloan Kettering Institute

Intracellular Targets for Cancer Immunotherapy

Bryan Zimdahl, Ph.D., Research Scientist, Preclinical Development, Eureka Therapeutics Inc.

 

Therapeutic Antibodies to Intracellular Targets in Cancer Therapy

Heehyoung Lee, Ph.D., ‪Director, Target Discovery and Validation, LA Cell, Inc‬.

‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

OPTIMIZATION AND CONTROL OF BINDING AND SPECIFICITY

In vivo Imaging of Probody™ Activation at the Tumor Site

Olga Vasiljeva, Ph.D., Associate Director, Head, Protease Biology, CytomX Therapeutics

Analyzing Specificity and Valency of Antibody Binding by Cell-Free Assays

Tilman Schlothauer, Ph.D., Principal Scientist, Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Germany

Highly Efficient Sweeping Antibody Using Novel Engineering Technology

Atsuhiko Maeda, Ph.D., Scientist, Biologics Discovery, Research Division, Chugai Pharmaceutical Co., Ltd., Japan

Achieving Selectivity Using Dual Targeting Bispecific Antibodies

Nicolas Fischer, Ph.D., Director, Research NovImmune SA, Switzerland

Computationally Driven Identification of Antibody Epitopes

Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, Dartmouth College




For questions about the meeting, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199
Email: ksimmons@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com